OTCMKTS:ADOCY Adocia (ADOCY) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ADOCY Stock Alerts $11.80 0.00 (0.00%) (As of 05/12/2023) Add Compare Share Share Today's Range$11.80▼$11.8050-Day Range$11.80▼$11.8052-Week Range$9.80▼$11.80VolumeN/AAverage VolumeN/AMarket Capitalization$168.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Adocia alerts: Email Address Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here About Adocia Stock (OTCMKTS:ADOCY)Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.Read More ADOCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADOCY Stock News HeadlinesApril 29, 2024 | finance.yahoo.comADOCIA Announces the Release of Its Universal Registration Document for the Year 2023April 26, 2024 | finance.yahoo.comADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial UpdateMay 11, 2024 | Porter & Company (Ad)Obama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.March 6, 2024 | finance.yahoo.comADOCIA Announces Its Participation at Key EventsFebruary 27, 2024 | finance.yahoo.comADOCIA Reports Fourth Quarter 2023 Financial Results and Provides a Business UpdateJanuary 25, 2024 | finance.yahoo.comADOCIA Announces its Financial Calendar for 2024November 9, 2023 | finance.yahoo.comADOCIA Revealed Promising Preclinical Data on AdoShell® Islets for Cell Therapy of DiabetesOctober 30, 2023 | finanznachrichten.deADOCIA's Partner Tonghua Dongbao Announces Positive Results of Three Clinical Trials on BioChaperone ComboMay 11, 2024 | Porter & Company (Ad)Obama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.October 25, 2023 | finance.yahoo.comADOCIA Reports Financial Results of Third Quarter 2023 and Provides an Update on its ActivitiesOctober 23, 2023 | finance.yahoo.comADOCIA’s Partner Tonghua Dongbao Announces Positive Results of Three Clinical Trials on BioChaperone® ComboSeptember 25, 2023 | finance.yahoo.comADOCIA Announces Oral Presentations on AdoShell® Islets at EASD and IPITA-IXA-CTRMS CongressesJuly 28, 2023 | markets.businessinsider.comKepler Capital Sticks to Their Buy Rating for Adocia SA (ADOIF)May 15, 2023 | msn.comAdocia names Olivier Soula CEOMay 6, 2023 | cbsnews.comCouncil of Islamic Organizations of Greater Chicago head to Springfield for Day of AdvocacyMarch 28, 2023 | forbes.comA Disability Advocacy Startup Strives To Model Its Own MissionJanuary 15, 2023 | finanznachrichten.deADOCIA Announces its Financial Calendar for 2023November 6, 2022 | reuters.comADOC.PA - Adocia SA | Stock Price & Latest News | ReutersOctober 6, 2022 | seekingalpha.comAdocia M1Pram shows weight loss benefit vs Lilly's Humalog in obese diabetic patients in trialOctober 5, 2022 | finance.yahoo.comADOCIA: Upcoming Investor MeetingsSeptember 21, 2022 | finance.yahoo.comADOCIA Announces First Half 2022 Financial Results and Provides a Business UpdateSeptember 15, 2022 | finance.yahoo.comAdocia Will Release Its 2022 Half-year Results on September 19th and Hold a Webinar on September 20thSeptember 8, 2022 | finance.yahoo.comADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 DiabetesAugust 26, 2022 | nz.finance.yahoo.comMary Kay Inc. Talks Conservation, Sustainability, and Corporate Responsibility During TNC Oceans PanelAugust 24, 2022 | finance.yahoo.comADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate UpdateJune 23, 2022 | finance.yahoo.comAdocia Publishes its Letter to ShareholdersJune 18, 2022 | nz.finance.yahoo.comBear market: What is the significance and how to spot navigate itSee More Headlines Receive ADOCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adocia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:ADOCY CUSIPN/A CIKN/A Webwww.adocia.com Phone33-04-72-61-06-10Fax33-04-72-36-39-67Employees97Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$18.30 million Price / Sales9.22 Cash FlowN/A Price / Cash FlowN/A Book Value($1.57) per share Price / Book-7.52Miscellaneous Outstanding Shares14,300,000Free FloatN/AMarket Cap$168.74 million OptionableNot Optionable Beta0.23 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Gérard Soula M.B.A. (Age 79)Ph.D., Co-Founder & Chairman of the Board Comp: $394.47kMr. Olivier Soula M.B.A. (Age 54)Ph.D., Co-Founder, CEO & Director Comp: $296.56kMs. Valérie DanaguezianChief Financial OfficerJeremy Benattar Eng.Pharm.D., Marketing & Strategy DirectorMs. Geraldine Favre SoulaHuman Resources Development DirectorDr. Bertrand AlluisHead of the Analysis Department and Project ManagerDr. David DuracherHead of the Pharmaceutical Development & Physical Chemistry Departments and Project ManagerDr. Richard CharvetHead of Chemistry Department & Project ManagerDr. Grégory MeiffrenHead of the Biology Department & Project ManagerRosy Eloy M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsOxford BiomedicaOTCMKTS:OXBDFPharma MarOTCMKTS:PHMMFSeres TherapeuticsNASDAQ:MCRBAlpha Tau MedicalNASDAQ:DRTSQuipt Home MedicalNASDAQ:QIPTView All Competitors ADOCY Stock Analysis - Frequently Asked Questions How have ADOCY shares performed in 2024? Adocia's stock was trading at $11.80 at the beginning of 2024. Since then, ADOCY shares have increased by 0.0% and is now trading at $11.80. View the best growth stocks for 2024 here. How do I buy shares of Adocia? Shares of ADOCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ADOCY) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adocia SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.